| Literature DB >> 35353995 |
Bradley S Johnson1, Shelby Rauh1, Daniel Tritz1, Michael Schiesel2, Matt Vassar1.
Abstract
INTRODUCTION: We aimed to assess the reproducibility of empirical research by determining the availability of components required for replication of a study, including materials, raw data, analysis scripts, protocols, and preregistration.Entities:
Mesh:
Year: 2021 PMID: 35353995 PMCID: PMC8328179 DOI: 10.5811/westjem.2021.3.50078
Source DB: PubMed Journal: West J Emerg Med ISSN: 1936-900X
Figure 1Flow diagram for included and excluded studies.
Characteristics of included publications.
| Characteristics | Variables | |
|---|---|---|
|
| ||
| N (%) | 95% CI | |
| Funding (N=364) | ||
| University | 5 (1.37) | 0.18–2.57% |
| Hospital | 7 (1.92) | 0.51–3.33% |
| Public | 46 (12.64) | 9.22–16.05% |
| Private/Industry | 23 (6.32) | 3.82–8.82% |
| Non-Profit | 3 (0.82) | 0–1.75% |
| Mixed | 43 (11.81) | 8.50–15.13% |
| No Statement Listed | 190 (52.20) | 47.07–57.33% |
| No Funding Received | 47 (12.91) | 9.47–16.36% |
| Type of study (N=364) | ||
| No Empirical Data | 112 (30.77) | 26.03–35.51% |
| Meta-Analysis | 10 (2.74) | 1.07–4.43% |
| Commentary | 1 (0.27) | 0–0.81% |
| Clinical Trial | 84 (23.08) | 18.75–27.41% |
| Case Study | 38 (10.44) | 7.30–13.58% |
| Case Series | 2 (0.55) | 0–0.75% |
| Cohort | 75 (20.60) | 16.45–24.76% |
| Case Control | 1 (0.27) | 0–0.81% |
| Survey | 20 (5.49) | 3.15–7.84% |
| Laboratory | 1 (0.27) | 0–0.81% |
| Other | 20 (5.49) | 3.15–7.84% |
| 5-Year impact factor (N=241) | ||
| Median | 2.333 | - |
| 1st Quartile | 1.408 | - |
| 3rd Quartile | 5.441 | - |
| Interquartile Range | 1.408 – 5.441 | - |
CI, confidence interval.
Additional characteristics of reproducibility in emergency medicine studies.
| Characteristics | Variables | |
|---|---|---|
|
| ||
| N (%) | 95% CI | |
| Open access (N=364) | ||
| Yes - found via Open Access | 122 (33.52) | 28.67–38.37% |
| Yes - found article via other means | 127 (34.89) | 29.99–39.79% |
| Could not access through paywall | 115 (31.59) | 26.82–36.37% |
| Protocol availability (N=212) | ||
| Full Protocol | 55 (25.94) | 20.04–31.84% |
| No Protocol | 157 (74.06) | 68.16–79.96% |
| Data availability (N=212) | ||
| Statement, some data are available | 13 (6.13) | 2.90–9.36% |
| Statement, data are not available | 8 (3.77) | 1.21–6.34% |
| No data availability statement | 191 (90.09) | 86.07–94.12% |
| Analysis Script Availability (N=212) | ||
| Statement, analysis scripts are not available | 0 | - |
| No analysis script availability statement | 212 | - |
| Pre-registration (N=212) | ||
| Statement, says was pre-registered | 83 (39.15) | 32.58–45.72% |
| Statement, says was not pre-registered | 1 (0.47) | 0–1.39% |
| No, there is no pre-registration statement | 128 (60.38) | 53.79–66.96% |
| Material availability (N=201) | ||
| Statement, some materials are available | 5 (2.49) | 0.33–4.64% |
| Statement, materials are not available | 0 | - |
| No materials availability statement | 196 (97.51) | 95.36–99.67% |
| Conflict of interest statement (N=364) | ||
| Statement, one or more conflicts of interest | 62 (17.03) | 13.17–20.89% |
| Statement. no conflict of interest | 170 (46.70) | 41.58–51.83% |
| No conflict-of-interest statement | 132 (36.26) | 31.32–41.20% |
| Replication studies (N=212) | ||
| Novel study | 211 (99.53) | - |
| Replication | 1 (0.47) | - |
| Cited in a systematic review/meta-analysis (a) (N=212) | ||
| No citations | 153 (72.17) | 66.14–78.20% |
| A single citation | 22 (10.38) | 6.27–14.48% |
| One to five citations | 8 (3.77) | 1.21–6.34% |
| Greater than five citations | 26 (12.26) | 7.85–16.68% |
| a - No studies were explicitly excluded from the systematic reviews or meta-analyses that cited the original article. | ||
| Most recent impact factor year (N=364) | ||
| 2014 | 0 | - |
| 2015 | 0 | - |
| 2016 | 0 | - |
| 2017 | 242 | - |
| 2018 | 85 | - |
| Not found | 37 | - |
Figure 2Recommendations for Promoting Reproducibility